Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infection

Journal of Medical Virology, Год журнала: 2023, Номер 95(4)

Опубликована: Апрель 1, 2023

The effect of nirmatrelvir plus ritonavir (NMV-r) on post-acute COVID-19 sequelae beyond 3 months SARS-CoV-2 infection remains unknown. This retrospective cohort study utilized data from the TriNetX Research Network. We identified nonhospitalized adult patients with receiving a diagnosis between January 1 and July 31, 2022. Propensity score matching (PSM) was used to create two matched cohorts: NMV-r non-NMV-r groups, respectively. measured primary outcomes using composite all-cause emergency room (ER) visits or hospitalization post-COVID-19 symptoms according WHO Delphi consensus, which also stated that post condition occurs usually onset COVID-19, during follow-up period 90 days after index end (180 days). Initially, we 12 247 received within 5 465 135 did not. After PSM, 245 remained in each group. During period, treated had lower risk ER compared untreated (659 vs. 955; odds ratio [OR], 0.672; 95% confidence interval [CI], 0.607-0.745; p < 0.0001). However, overall not significantly differ groups (2265 2187; OR, 1.043; CI, 0.978-1.114; = 0.2021). reduced group similarities were consistent subgroups stratified by sex, age, vaccination status. Early treatment associated 90-180 no treatment; however, mortality groups.

Язык: Английский

---

Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis

Journal of Infection, Год журнала: 2024, Номер 89(2), С. 106190 - 106190

Опубликована: Июнь 2, 2024

Язык: Английский

---

Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19

Journal of Medical Virology, Год журнала: 2023, Номер 95(6)

Опубликована: Июнь 1, 2023

Abstract The aim of this study was to investigate the clinical efficacy a combination nirmatrelvir and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This retrospective cohort used TriNetX research network identify adult diabetic between January 1, 2020, December 31, 2022. Propensity score matching match who received NMV‐r (NMV‐r group) those did not receive (control group). primary outcome all‐cause hospitalization or death during 30‐day follow‐up period. Two cohorts comprising 13 822 balanced baseline characteristics were created using propensity matching. During period, group had lower risk than control (1.4% [ n = 193] vs. 3.1% 434]; hazard ratio [HR], 0.497; 95% confidence interval [CI], 0.420–0.589). Compared group, also (HR, 0.606; CI, 0.508–0.723) mortality 0.076; 0.033–0.175). consistently observed almost all subgroup analyses, which examined sex (male: 0.520 [0.401–0.675]; female: 0.586 [0.465–0.739]), age (age 18–64 years: 0.767 [0.601–0.980]; ≥65 0.394 [0.308–0.505]), level HbA1c (<7.5%: 0.490 [0.401–0.599]; ≥7.5%: 0.655 [0.441–0.972]), unvaccinated (0.466 [0.362–0.599]), type 1 DM (0.453 [0.286–0.718]) 2 (0.430 [0.361–0.511]). can help reduce nonhospitalized COVID‐19.

Язык: Английский

---

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors

Journal of Infection, Год журнала: 2023, Номер 86(4), С. e107 - e110

Опубликована: Фев. 10, 2023

Язык: Английский

---

Effectiveness of oral antiviral agents on long‐term cardiovascular risk in nonhospitalized patients with COVID‐19: A multicenter matched cohort study

Journal of Medical Virology, Год журнала: 2023, Номер 95(8)

Опубликована: Июль 31, 2023

Abstract Although a novel oral antiviral agent can improve short‐term COVID‐19 outcomes, its effects on the long‐term namely risk of major adverse cardiovascular events (MACEs), remains unknown. This retrospective cohort study used TriNetX research network to identify nonhospitalized adult patients with between March 1, 2020, and January 2022. A propensity score matching method was form two matched cohorts without receiving nirmatrelvir–ritonavir (NMV‐r) or molnupiravir. The primary outcome incidence MACEs within 30‐day 1‐year period following diagnosis COVID‐19. Two each 80 888 balanced baseline characteristics were formed using matching. During follow‐up period, 976 in group 1609 control developed MACE. Overall, had significantly lower MACE than (hazard ratio [HR], 0.683; 95% confidence interval: 0.630–0.739). HRs overall consistently observed most subgroup analyses (age: >41–≤64 years: 0.60 [0.52–0.89]; age: ≥65 0.68 [0.62–0.76]; women: 0.63 [0.57–0.71]; men: 0.62 [0.55–0.70]; vaccinated: 0.74 [0.63–0.88]; unvaccinated: 0.66 [0.60–0.73]; NMV‐r; 0.65 [0.59–0.71]; molnupiravir: 0.75 [0.61–0.92]). In conclusion, agents, NMV‐r molnupiravir, effective reducing among COVID‐19, particularly when treated aged ≥40 years. These findings suggest potential role agents as preventive measure reduce further outcomes.

Язык: Английский

---

Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19

International Journal of Antimicrobial Agents, Год журнала: 2023, Номер 62(6), С. 106984 - 106984

Опубликована: Сен. 27, 2023

Язык: Английский

---

Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID‐19 and substance use disorders based on real‐world data

Journal of Medical Virology, Год журнала: 2023, Номер 95(5)

Опубликована: Май 1, 2023

Abstract This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV‐r) in treating patients with coronavirus disease‐2019 (COVID‐19) and substance use disorders (SUDs). included two cohorts: first examined SUDs, without a prescription for NMV‐r, while second compared prescribed diagnosis SUDs. SUDs were defined using ICD‐10 codes, related to including alcohol, cannabis, cocaine, opioid, tobacco (TUD). Patients underlying COVID‐19 identified TriNetX network. We used 1:1 propensity score matching create balanced groups. The primary outcome interest was composite all‐cause hospitalization or death within 30 days. Propensity yielded matched groups 10 601 each. results showed that NMV‐r associated lower risk death, days after (hazard ratio (HR), 0.640; 95% confidence interval (CI): 0.543–0.754), as well (HR, 0.699; CI: 0.592–0.826) 0.084; 0.026–0.273). However, had higher hospitalized than those even 1.783; 1.399–2.271). also found prevalence comorbidities adverse socioeconomic determinants health Subgroup analysis benefits consistent across most subgroups different characteristics, age (patients aged ≥60 years [HR, 0.507; 0.402–0.640]), sex (women 0.636; 0.517–0.783] men 0.480; 0.373–0.618]), vaccine status (vaccinated <2 doses 0.514; 0.435–0.608]), SUD subtypes (alcohol disorder 0.711; 0.511– 0.988], TUD 0.666; 0.555–0.800]) Omicron wave 0.624; 0.536–0.726). Our findings indicate could reduce treatment among support COVID‐19.

Язык: Английский

---

The effect of nirmatrelvir‐ritonavir on the long‐term risk of neuropsychiatric sequelae following COVID‐19

Journal of Medical Virology, Год журнала: 2023, Номер 95(7)

Опубликована: Июль 1, 2023

Abstract The retrospective cohort was conducted to assess the effect of nirmatrelvir‐ritonavir (NMV‐r) on long‐term risk neuropsychiatric sequela following COVID‐19. TriNetX research network used identify nonhospitalized adult patients who tested positive for severe acute respiratory syndrome coronavirus 2 infection or were diagnosed with COVID‐19 between March 1, 2020 and July 2022. Further propensity score matching method create two matched cohorts without receiving NMV‐r. primary outcome incidence within a 90‐day 1‐year period diagnosis After screening 119 494 527 electronic health records, each 27 194 identified. During follow‐up period, NMV‐r group demonstrated reduced any sequelae compared control (odds ratio [OR], 0.634; 95% confidence interval [CI], 0.604−0.667). In comparison group, patient treated exhibited markedly diminished developing neurocognitive (OR, 0.377; CI, 0.325−0.439) psychiatric 0.629; 0.593−0.666). addition, had significantly dementia 0.365; 0.255−0.522), depression 0.555; 0.503−0.612), insomnia 0.582; 0.508−0.668) anxiety disorder 0.645 0.600−0.692). Moreover, beneficial observed across further subgroup analyses. Among patients, at disease progression, use is associated reduction in sequela, including dementia, depression, disorder. It may be necessary re‐evaluate NMV‐r, as preventive measure reduce post‐acute adverse mental outcomes.

Язык: Английский

---

Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: A one-year retrospective cohort analysis of 33,908 patients

Brain Behavior and Immunity, Год журнала: 2023, Номер 114, С. 453 - 461

Опубликована: Сен. 15, 2023

Early prevention and management of psychiatric symptoms in long COVID (or post-COVID-19 conditions) are crucial for reducing long-term disability. Existing clinical guidelines recommend the use omega-3 polyunsaturated fatty acids (PUFAs) as a promising therapeutic approach various common disorders due to their anti-inflammatory neuroprotective characteristics. This study aims investigate potential efficacy PUFAs alleviating sequelae following COVID-19.This 1-year retrospective cohort used TriNetX electronic health records network examine effects supplements on adults diagnosed with COVID-19. Using propensity-score matching, compared those who did not, assessing outcomes including depression, anxiety disorders, insomnia, other somatic conditions up year after COVID-19 diagnosis.In 16,962 patients received 2,248,803 supplementation significantly reduced risk developing diagnosis (HR, 0.804; 95% CI, 0.729 0.888). Specifically, risks depression 0.828; 0.714 0.960), 0.833; 0.743 0.933), insomnia 0.679; 0.531 0.869) were group. effect was consistent across sex, race, 18-59 age group, less than two doses vaccine. The group also had lower cough myalgia, but no significant difference noted like chest pain, abnormal breathing, abdominal issues, fatigue, headache, cognitive symptoms.Omega-3 may require re-evaluation preventive strategy against adverse mental placebo-controlled trials.

Язык: Английский

---

Clinical effectiveness of nirmatrelvir plus ritonavir on the short‐ and long‐term outcome in high‐risk children with COVID‐19

Journal of Medical Virology, Год журнала: 2024, Номер 96(5)

Опубликована: Май 1, 2024

This study investigated the clinical effectiveness of nirmatrelvir plus ritonavir (NMV-r) on short-term outcome and risk postacute sequelae severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) among pediatric patients with disease 2019 (COVID-19). retrospective cohort used TriNetX research network to identify between 12 18 years COVID-19 January 1, 2022 August 31, 2023. The propensity score matching (PSM) method was match receiving NMV-r (NMV-r group) those who did not receive (control group). Two cohorts comprising 633 each control groups), balanced baseline characteristics, were identified using PSM method. During initial 30 days, group showed a lower incidence all-cause hospitalization, mortality, or ED visits (hazard ratio [HR] = 0.546, 95% confidence interval [CI]: 0.372-0.799, p 0.002). Additionally, had significantly hospitalization compared (HR 0.463, CI: 0.269-0.798), no deaths occurring in either group. In 30-180-day follow-up period, exhibited non-significantly post-acute SARS-CoV-2 (PASC), encompassing symptoms such as fatigue, cardiopulmonary symptoms, pain, cognitive impairments, headache, dizziness, sleep disorders, anxiety, depression, underscores potential treating high-risk COVID-19, demonstrating significant reductions adverse outcomes emergency department visits, mortality within 30-day period. shows promise potentially preventing development PASC.

Язык: Английский

---